New insider activity at Bio Green Med Solution ( (BGMS) ) has taken place on October 20, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Significant shareholder Khai Loon Kua has offloaded 95,683 shares of Bio Green Med Solution, amounting to a transaction value of $413,669. Additionally, FITTERS Diversified Berhad, another significant shareholder, sold 26,051 shares, resulting in a sale worth $143,280.
Recent Updates on BGMS stock
Bio Green Med Solution (BGMS) has recently made significant strategic moves, including finalizing an Asset Purchase Agreement with Tethra Biosciences Inc. for the sale of assets related to Plogosertib, which could impact its market positioning. Additionally, the company announced a quarterly cash dividend on its preferred stock, indicating a focus on shareholder returns. Despite these developments, the stock is rated as ‘Underperform’ by Spark, TipRanks’ AI Analyst, due to ongoing financial strain, operational inefficiencies, and unattractive valuation metrics such as a negative P/E ratio and lack of dividend yield. The company’s technical sentiment signal remains a ‘Strong Sell,’ reflecting the challenging market conditions it faces.
Spark’s Take on BGMS Stock
According to Spark, TipRanks’ AI Analyst, BGMS is a Underperform.
Cyclacel Pharmaceuticals is currently under significant financial strain, marked by operational inefficiencies and a weak financial position, as reflected in its low financial performance score. While the technical indicators suggest a neutral trend, the valuation is unattractive due to its negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.
To see Spark’s full report on BGMS stock, click here.
More about Bio Green Med Solution
YTD Price Performance: -95.52%
Average Trading Volume: 453,406
Technical Sentiment Signal: Strong Sell
Current Market Cap: $9.05M